TWI880021B - 半胱胺酸工程改造抗體之結合物 - Google Patents

半胱胺酸工程改造抗體之結合物 Download PDF

Info

Publication number
TWI880021B
TWI880021B TW110132303A TW110132303A TWI880021B TW I880021 B TWI880021 B TW I880021B TW 110132303 A TW110132303 A TW 110132303A TW 110132303 A TW110132303 A TW 110132303A TW I880021 B TWI880021 B TW I880021B
Authority
TW
Taiwan
Prior art keywords
ala
group
conjugate
val
leu
Prior art date
Application number
TW110132303A
Other languages
English (en)
Chinese (zh)
Other versions
TW202146057A (zh
Inventor
尼可拉斯 Ｃ 由達
晨 白
麥克 路易斯 米勒
Original Assignee
美商免疫原公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商免疫原公司 filed Critical 美商免疫原公司
Publication of TW202146057A publication Critical patent/TW202146057A/zh
Application granted granted Critical
Publication of TWI880021B publication Critical patent/TWI880021B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW110132303A 2015-06-29 2016-06-29 半胱胺酸工程改造抗體之結合物 TWI880021B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562186254P 2015-06-29 2015-06-29
US62/186,254 2015-06-29
US201662338245P 2016-05-18 2016-05-18
US62/338,245 2016-05-18

Publications (2)

Publication Number Publication Date
TW202146057A TW202146057A (zh) 2021-12-16
TWI880021B true TWI880021B (zh) 2025-04-11

Family

ID=56409216

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110132303A TWI880021B (zh) 2015-06-29 2016-06-29 半胱胺酸工程改造抗體之結合物
TW105120514A TWI740833B (zh) 2015-06-29 2016-06-29 半胱胺酸工程改造抗體之結合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105120514A TWI740833B (zh) 2015-06-29 2016-06-29 半胱胺酸工程改造抗體之結合物

Country Status (24)

Country Link
US (3) US10898579B2 (enExample)
EP (2) EP3769787A1 (enExample)
JP (4) JP6843080B2 (enExample)
KR (1) KR102793098B1 (enExample)
CN (2) CN113769108B (enExample)
AR (1) AR106013A1 (enExample)
AU (2) AU2016285929B2 (enExample)
CA (1) CA2988806C (enExample)
CY (1) CY1123606T1 (enExample)
DK (1) DK3313845T3 (enExample)
ES (1) ES2832527T3 (enExample)
HR (1) HRP20201790T1 (enExample)
HU (1) HUE052616T2 (enExample)
LT (1) LT3313845T (enExample)
MA (1) MA42250B1 (enExample)
MD (1) MD3313845T2 (enExample)
PL (1) PL3313845T3 (enExample)
PT (1) PT3313845T (enExample)
RS (1) RS61050B1 (enExample)
RU (1) RU2733740C2 (enExample)
SI (1) SI3313845T1 (enExample)
SM (1) SMT202000614T1 (enExample)
TW (2) TWI880021B (enExample)
WO (1) WO2017004025A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240063203A (ko) 2015-06-29 2024-05-09 이뮤노젠 아이엔씨 항-cd123 항체 및 이들의 접합체와 유도체
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
CN116813690A (zh) 2016-11-23 2023-09-29 伊缪诺金公司 苯并二氮䓬衍生物的选择性磺化
EP3558391B1 (en) 2016-12-23 2022-02-02 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
WO2018183494A1 (en) 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
WO2019060718A1 (en) * 2017-09-22 2019-03-28 Immunogen, Inc. SEPARATION OF LIGHT TRIPLE CHAIN ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY
JP7273716B2 (ja) 2017-09-29 2023-05-15 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
EP3873524B8 (en) 2018-10-30 2025-04-09 ImmunoGen, Inc. Methods of treatment using anti-cd123 immunoconjugates
IL283047B2 (en) * 2018-11-12 2024-04-01 Immunogen Inc Methods for preparing cytotoxic benzodiazepine derivatives
CA3119358A1 (en) * 2018-11-12 2020-05-22 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
KR20210091711A (ko) 2018-11-14 2021-07-22 다이이찌 산쿄 가부시키가이샤 항 cdh6 항체-피롤로벤조디아제핀 유도체 컨쥬게이트
TW202102270A (zh) * 2019-03-21 2021-01-16 美商伊繆諾金公司 製備細胞結合劑-藥物結合物之方法
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
SG11202109860VA (en) 2019-03-25 2021-10-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
BR112021017350A2 (pt) 2019-03-27 2021-11-16 Daiichi Sankyo Co Ltd Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
US11701428B2 (en) 2019-04-29 2023-07-18 Immunogen, Inc. Therapeutic combinations comprising anti-CD123 immunoconjugates
TW202227479A (zh) 2020-09-02 2022-07-16 日商第一三共股份有限公司 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶
EP4277664A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
EP4442828A4 (en) 2021-11-30 2025-11-12 Daiichi Sankyo Co Ltd Masked antibodies cleavable by protease
US20250170255A1 (en) 2022-02-09 2025-05-29 Daiichi Sankyo Company, Limited Environmentally-responsive masked antibody and use thereof
KR20240155298A (ko) 2022-03-02 2024-10-28 다이이찌 산쿄 가부시키가이샤 Fc 함유 분자의 제조 방법
WO2025235918A1 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm
WO2025235924A2 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
JP2003514903A (ja) 1999-11-24 2003-04-22 イムノージェン インコーポレーテッド タキサンを含有する細胞傷害薬とその治療への利用
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
JP2005539009A (ja) 2002-08-02 2005-12-22 イミュノジェン・インコーポレーテッド 新規の効力のあるタキサンを含む細胞毒性物質、および、それらの治療用途
ATE499116T1 (de) 2002-08-16 2011-03-15 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
KR20050059332A (ko) 2002-11-07 2005-06-17 이뮤노젠 아이엔씨 항-씨디33 항체와 이를 이용한 급성 골수성 백혈병의치료방법
SI1592457T1 (sl) * 2003-01-27 2012-12-31 Endocyte, Inc. Konjugat folat-vinblastin kot zdravilo
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ES2533695T3 (es) 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
CN104524592B (zh) 2008-04-30 2018-06-05 伊缪诺金公司 交联剂和它们的用途
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
CN102365021B (zh) * 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
US8431416B2 (en) * 2009-04-01 2013-04-30 Becton, Dickinson And Company Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2011092838A1 (ja) 2010-01-29 2011-08-04 株式会社フォーサイド・ドット・コム コンテンツ共有システム、およびコンテンツ共有方法
SMT201700139T1 (it) 2010-02-24 2017-05-08 Immunogen Inc Immunoconiugati contro il recettore 1 del folato e relativi usi
MY177062A (en) 2010-03-12 2020-09-03 Debiopharm Int Sa Cd37-binding molecules and immunoconjugates thereof
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
CN103328505B (zh) 2010-10-29 2015-12-02 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
EP2632490A4 (en) 2010-10-29 2014-10-22 Immunogen Inc NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
SMT201900181T1 (it) * 2011-02-15 2019-05-10 Immunogen Inc Metodi di preparazione di coniugati
WO2013177481A1 (en) * 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
EP2961434A2 (en) * 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
WO2014134457A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
SI3129406T1 (sl) * 2014-04-11 2019-04-30 Medimmune, Llc Konjugirane spojine, ki vsebujejo cisteinsko konstruirana protitelesa
RU2017101681A (ru) * 2014-06-20 2018-07-20 Биоэллаенс К.В. Конъюгаты анти-cd22 антитело - лекарственное средство и способы их применения
EP3157560A4 (en) * 2014-06-20 2018-02-21 Abgenomics International Inc. Her2 antibody-drug conjugates
SG11201610620UA (en) * 2014-06-20 2017-01-27 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
CA2958882A1 (en) * 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
MA41645A (fr) 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
KR20240063203A (ko) 2015-06-29 2024-05-09 이뮤노젠 아이엔씨 항-cd123 항체 및 이들의 접합체와 유도체
CN116813690A (zh) * 2016-11-23 2023-09-29 伊缪诺金公司 苯并二氮䓬衍生物的选择性磺化

Also Published As

Publication number Publication date
JP2021088581A (ja) 2021-06-10
CN113769108B (zh) 2024-11-08
RS61050B1 (sr) 2020-12-31
TW201705983A (zh) 2017-02-16
CA2988806C (en) 2024-09-10
JP2018528162A (ja) 2018-09-27
SMT202000614T1 (it) 2021-01-05
JP2022163185A (ja) 2022-10-25
CN107708810A (zh) 2018-02-16
EP3769787A1 (en) 2021-01-27
JP7441281B2 (ja) 2024-02-29
RU2017144859A3 (enExample) 2019-12-02
HUE052616T2 (hu) 2021-05-28
AU2016285929A1 (en) 2018-01-04
US20250011340A1 (en) 2025-01-09
CN113769108A (zh) 2021-12-10
MD3313845T2 (ro) 2021-02-28
PT3313845T (pt) 2020-11-19
CA2988806A1 (en) 2017-01-05
TW202146057A (zh) 2021-12-16
ES2832527T3 (es) 2021-06-10
RU2733740C2 (ru) 2020-10-06
JP6843080B2 (ja) 2021-03-17
JP2024067036A (ja) 2024-05-16
MA42250B1 (fr) 2020-11-30
KR102793098B1 (ko) 2025-04-09
AR106013A1 (es) 2017-12-06
EP3313845B1 (en) 2020-08-12
AU2016285929B2 (en) 2022-01-06
EP3313845A1 (en) 2018-05-02
RU2017144859A (ru) 2019-07-30
AU2022202208B2 (en) 2024-08-08
HK1254782A1 (en) 2019-07-26
WO2017004025A1 (en) 2017-01-05
LT3313845T (lt) 2020-12-10
PL3313845T3 (pl) 2021-01-11
US20170014522A1 (en) 2017-01-19
US20210085800A1 (en) 2021-03-25
MA42250A (fr) 2018-05-02
HRP20201790T1 (hr) 2021-02-05
US10898579B2 (en) 2021-01-26
DK3313845T3 (da) 2020-11-16
CN107708810B (zh) 2021-10-22
SI3313845T1 (sl) 2021-01-29
KR20180021176A (ko) 2018-02-28
AU2022202208A1 (en) 2022-04-21
TWI740833B (zh) 2021-10-01
CY1123606T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
TWI880021B (zh) 半胱胺酸工程改造抗體之結合物
KR102638901B1 (ko) 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
TWI757759B (zh) 細胞毒性苯并二氮呯衍生物
RU2834224C1 (ru) Конъюгаты сконструированных антител с цистеиновыми заменами
HK40044772A (en) Conjugates of cysteine engineered antibodies
HK40046012A (en) Cytotoxic benzodiazepine derivatives
HK1254782B (en) Conjugates of cysteine engineered antibodies
HK1236943B (en) Cytotoxic benzodiazepine derivatives
HK1236943A1 (en) Cytotoxic benzodiazepine derivatives